Orforglipron / LY-3502970

Metabolic / fat loss

Appetite, glucose, weight, and metabolic regulation

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Incretin / metabolic peptide or small molecule
Primary mechanism: Incretin/amylin/glucagon-axis receptor modulation
Primary market use: Metabolic / fat loss

Pharmacology

Oral bioavailability: Route-dependent / verify
Half-life: ~25–68 h reported range
Route tags: Route-dependent / verify
Evidence level: Vendor/source-list + secondary signal
Clinical status: Research/reference; verify status
Value-for-money score: 8 / 10

Reported protocol signal

Vendor product-form signal only, not a protocol: ORFORGLIPRON (LY-3502970) PEPTIDE POWDER (30 TABLETS) (10MG/TABLET, 300MG TOTAL) | ORFORGLIPRON (LY-3502970) PEPTIDE POWDER (60 CAPSULES) (10MG/CAPSULE, 600MG TOTAL)

For orientation only. See disclaimer — always consult a licensed clinician before use.

Stackability

Commonly compared/stacked in metabolic and body-composition protocols; verify redundancy and risk.

Notes

Not found in current uploaded master database by normalized name/alias comparison; candidate for review/import.